You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Upon entering the agreement, Aspire purchased $1 million in common stock, and may purchase up to $14 million more at Biocept's discretion.
The company is now offering a test covering about 3,000 hotspots in 50 genes for 10 cancer types that can be performed on sample volumes as low as 50 microliters.
The partners will use Biocept's liquid biopsy systems to detect estrogen receptor gene mutations that could help guide treatment for women with breast cancer.
Pacific Biosciences announced this week that it has reached the final developmental milestone of its commercialization and licensing agreement with Roche.
The German firm hopes that increasing awareness among oncologists about the benefits of liquid biopsy will spur adoption of the test, called NEOliquid.
The company said it would use the money to further develop and refine its proprietary circulating tumor cell identification and isolation technology.
Guardant said Labco would distribute its liquid biopsy test in Europe and South America and also work toward gaining reimbursement for the test in those countries.
The work identified specific groups of somatic mutations that might be ideal to hunt for in ctDNA to monitor tumor burden, guide treatment, or follow therapeutic response.
The partners will conduct multiple studies to analyze circulating tumor cells to find biomarkers that could predict a patient's response to treatment.
In Science this week: Cas9 DNA-cutting mechanism explored, and more.
A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.
A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.
The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.
In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.